ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- PMID: 27380959
- DOI: 10.1093/annonc/mdw235
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Abstract
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Keywords: ESMO; clinical practice guidelines; colorectal cancer; consensus.
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Comment in
-
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?Ann Oncol. 2017 Jan 1;28(1):183. doi: 10.1093/annonc/mdw448. Ann Oncol. 2017. PMID: 27687313 No abstract available.
-
Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Ann Oncol. 2017 Jan 1;28(1):184. doi: 10.1093/annonc/mdw533. Ann Oncol. 2017. PMID: 27701067 No abstract available.
-
DPD testing must remain a recommended option, but not a recommended routine test.Ann Oncol. 2017 Jun 1;28(6):1399. doi: 10.1093/annonc/mdx118. Ann Oncol. 2017. PMID: 28327971 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical